GMTX Research and Charts

GMTX - Gemini Therapeutics Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-10-21)

Last 86.17	Change ⇓ -1.00 (-1.15%)	Volume 1,743,251
	Open 85.64	High 88.10	Low 85.02

8EMA (Daily) 80.31	40EMA (Daily) 68.43	50EMA (Daily) 66.80	STO (Daily) 77.032	MACD Hist (Daily) 1.798
8EMA (Weekly) 73.436	40EMA (Weekly) 59.55	50EMA (Weekly) 58.05	STO (Weekly) 87.658	MACD Hist (Weekly) 3.144


Company Profile
Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health. Variations in the gene that encodes CFH strongly correlate with an increased risk of developing AMD.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.